1. Study identification
EU PAS Register NumberEUPAS36734
Official titleVALIDATION STUDY PROTOCOL (OP0007) FOR THE EUROPEAN NON-INTERVENTIONAL POST- AUTHORIZATION SAFETY STUDY RELATED TO SERIOUS CARDIOVASCULAR EVENTS OF MYOCARDIAL INFARCTION AND STROKE AND ALL-CAUSE MORTALITY FOR ROMOSOZUMAB BY THE EU-ADR ALLIANCE (OP0004) AND EUROPEAN NON-INTERVENTIONAL POST-AUTHORIZATION SAFETY STUDY RELATED TO SERIOUS INFECTIONS FOR ROMOSOZUMAB BY THE EU-ADR ALLIANCE (OP0006)
Study title acronym
Study typeOther: Outcome validation study for real-world data
Brief description of the studyThe objective of this study is to determine the completeness and diagnostic validity of the following outcomes, which will be evaluated in the 2 European non-interventional post-authorisation safety studies (PASS) of romosozumab: 1. cardiovascular death; 2. myocardial infarction; 3. Stroke; 4. serious infection. Outcomes will be identified based on predefined code lists, which were adapted according to the relevant coding system for the respective database. Validation algorithms are defined individually for each specific outcome. In addition, the validation procedures, e.g. manual free text evaluation, will depend on the specific characteristics of the individual databases (primary care and claims databases). Validation of the outcomes of interest will be conducted for databases where previous validation demonstrated insufficient positive predictive values (PPVs) <75% (all-case validation), or where validation has not yet been performed (sample validation of 250 cases).
Was this study requested by a regulator?No
Is the study required by a Risk Management Plan (RMP)?
Not applicable
Regulatory procedure number (RMP Category 1 and 2 studies only)
Other study registration identification numbers and URLs as applicable
2. Research centres and Investigator details
Coordinating study entity
Centre nameUCB Biosciences GmbH
Centre locationMonheim, Germany
Details of (Primary) lead investigator
Title Dr
Last name Personal data of lead investigator will not be disclosed because his/her consent required for disclosure according to applicable data protection laws is not available.
First name Clinical Trial Registries and Results
Is this study being carried out with the collaboration of a research network?
Yes
EU-ADR Alliance
Other centres where this study is being conducted
Multiple centres
In total how many centres are involved in this Study?5
Countries in which this study is being conducted
International study
Germany
Italy
Netherlands
Spain
3. Study timelines: initial administrative steps, progress reports and final report
PlannedActual
Date when funding contract was signed30/09/202030/09/2020
Start date of data collection01/10/202001/10/2020
Start date of data analysis30/09/2026
Date of interim report, if expected
Date of final study report31/03/2027
4. Sources of funding
Please provide estimates of the percentage of funding by source for this study
Names(s)Approximate % funding
Pharmaceutical companiesUCB Biopharma SRL100
Charities
Government body
Research councils
EU funding scheme
5. Contact details for enquiries
Scientific Enquiries
Title Dr
Last name Personal data of lead investigator will not be disclosed because his/her consent required for disclosure according to applicable data protection laws is not available.
First name Clinical Trial Registries and Results
Address line 1Alfred-Nobel-Strasse 10
Address line 2Not applicable
Address line 3Not applicable
CityMonheim
Postcode
CountryGermany
Phone number (incl. country code)492173481515
Alternative phone number
Fax number (incl. country code)
Public Enquiries
Title Dr
Last name Personal data of lead investigator will not be disclosed because his/her consent required for disclosure according to applicable data protection laws is not available.
First name Clinical Trial Registries and Results
Address line 1Alfred-Nobel-Strasse 10
Address line 2Not applicable
Address line 3Not applicable
CityMonheim
Postcode
CountryGermany
Phone number (incl. country code)492173481515
Alternative phone number
Fax number (incl. country code)
6. Study drug(s) information
Product NameEvenity
CountryBelgium
Substance INN(s)ROMOSOZUMAB
7. Medical conditions to be studied
Medical condition(s)Yes
Osteoporosis postmenopausal
8. Population under study
Age
Adults (45 - 64 years)
Adults (65 - 74 years)
Adults (75 years and over)
Sex
Female
9. Number of subjects
Estimated total number of subjects250
Additional information
For databases where the outcome of interest was not previously validated, sample validation of 250 cases will be performed. However, all cases will be validated for outcomes where insufficient PPV (positive predictive value) of <75% (point estimates) is demonstrated in the sample validation.
10. Source of data
Is this study being carried out with an established data source?Yes
Data sources registered with ENCePP
Data sources not registered with ENCePP
Health Search Database (HSD), Italy
Sources of data
Administrative database, e.g. claims database
Routine primary care electronic patient registry
11. Scope of the study
What is the scope of the study?
Validation of real-world data
Primary scope : Validation of real-world data
12. Main objective(s)
What is the main objective of the study?
The objective of this study is to determine the completeness and diagnostic validity of the following outcomes, which will be evaluated in the 2 European non-interventional PASS of romosozumab: 1. cardiovascular death; 2. myocardial infarction; 3. Stroke; 4. serious infection.
Are there primary outcomes?Yes
Validation of 4 main outcomes in 2 PASS studies
Are there secondary outcomes?No
13. Study design
What is the design of the study?
Outcome validation study
14. Follow-up of patients
Will patients be followed up?Not applicable/no follow-up
15. Data analysis plan
Please provide a brief summary of the analysis method
In patients eligible for each of 2 PASS studies, outcomes will be identified based on predefined code lists, which were adapted according to the relevant coding system for the respective databases. All validations (either sample or all-case validations) will be based on free text review of the individual cases. Primary care charts and any related documents (e.g. specialist letters, referrals) will be reviewed by clinically trained validators blinded to exposure. The algorithms for the validation of each of 4 outcomes is provided. Adaptations and specifications to the algorithm may be required to adapt the algorithm to database-specific needs.